amiratx.com
  • Home
  • AMI463
  • Pipeline
  • Partners
  • Resources
  • Contact
Select Page

RCAN1-mediated calcineurin inhibition as a target for cancer therapy

by Sergi | Jun 22, 2022 | AMI605, Scientific Papers

By Mengyi Lao, Xiaozhen Zhang, Hanshen Yang, Xueli Bai, and Tingbo Liang Molecular Medicine volume 28, Article number: 69 (2022) DOI: https://doi.org/10.1186/s10020-022-00492-7 Abstract Cancer is the leading cause of mortality worldwide. Regulator of calcineurin...

Recent knowledge of NFATc4 in oncogenesis and cancer prognosis

by Sergi | Jun 13, 2022 | AMI605, Scientific Papers

By Zhong, QH., Zha, SW., Lau, A.T.Y. et al. Cancer Cell International 22, 212 (2022). https://doi.org/10.1186/s12935-022-02619-6 Abstract Nuclear factor of activated T-cells, cytoplasmic 4 (NFATc4), a transcription factor of NFAT family, which is activated by...

Recent Posts

  • Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States
  • Cell biology of protein–lipid conjugation
  • Targeting the Hedgehog Pathway in Rhabdomyosarcoma
  • RCAN1-mediated calcineurin inhibition as a target for cancer therapy
  • Recent knowledge of NFATc4 in oncogenesis and cancer prognosis

Recent Comments

No comments to show.

Privacy Policy

Legal Notice

Cookie Policy

Related Publications

  • 2024
  • 2023
  • 2022
Ready to help children beat cancer
  • X
  • RSS
© 2023 Amira Therapeutics, SL